IT
Iona Taylor
Also known as: Iona J Brian
University of Oxford, University of Edinburgh
Research areas: Medicine · Infectious Diseases · Malaria Research and Control · SARS-CoV-2 and COVID-19 Research · COVID-19 Clinical Research Studies
0000-0002-2287-9488
Employment
- 2014 - 2022
- 2013 - 2013
Education
-
University of Edinburgh BSc (Hons) Zoology2010 - 2014
Projects & Funding
Projects & funding information is unavailable.
Publications (33)
- Vaccination with Plasmodium vivax Duffy-binding protein inhibits parasite growth during controlled human malaria infection Save
- Vaccination with Plasmodium vivax Duffy-binding protein inhibits parasite growth during controlled human malaria infection Save
- Vaccination with Plasmodium vivax Duffy-binding protein inhibits parasite growth during controlled human malaria infection. Save
- Impact of a blood-stage vaccine on Plasmodium vivax malaria Save
- Impact of a blood-stage vaccine on Plasmodium vivax malaria Save
- Controlled human malaria infection with a clone of Plasmodium vivax with high-quality genome assembly Save
- Controlled human malaria infection with a clone of Plasmodium vivax with high-quality genome assembly Save
- Controlled human malaria infection with a clone of Plasmodium vivax with high-quality genome assembly. Save
- Controlled human malaria infection with PvW1 – a new clone of Plasmodium vivax with high quality genome assembly Save
- Safety and Immunogenicity of ChAd63/MVA Pfs25-IMX313 in a Phase I First-in-Human Trial Save
- Author Correction: Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses. Save
- Author Correction: T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1/2 clinical trial. Save
- Reduced blood-stage malaria growth and immune correlates in humans following RH5 vaccination Save
- Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials. Save
- Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses. Save
- Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Save
- T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1/2 clinical trial. Save
- Naturally Acquired Rift Valley Fever Virus Neutralizing Antibodies Predominantly Target the Gn Glycoprotein Save
- Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial. Save
- Naturally acquired Rift Valley fever virus neutralizing antibodies predominantly target the Gn glycoprotein Save